The new drug for severe asthma that emerged joined the competition with the five existing biologics that were being used in Korea. AstraZeneca, which recently received domestic approval for its new drug, plans to differentiate itself from existing treatment options with new mechanisms of action and formulations.

According to industry sources on the 26th, AstraZeneca Korea's severe asthma drug Tezspire (tezepelumab) was recently approved in Korea.

This brings the total number of biologics approved for the treatment of severe asthma in Korea to six, following Novartis Xolair (omalizumab) and GSK Nucala (mepolizumab) in 2016, Teva-Handok's Cinquar (reslizumab) in 2017, AstraZeneca’s Fasenra